CyFlow CD8a Purified (RUO)
| 品番 | CC027137 | ||
|---|---|---|---|
| 抗体名 | Anti-Ms CD8A PURI,53-6.7 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
- | ||
| 反応性|交差吸着 | Mouse | レーザー | - |
| 抗原 | CD8a, T8, Leu2 | 最大蛍光波長 | - |
| クローン | 53-6.7 | 最大励起波長 | - |
| ホスト | Rat | 標識/Format | Purified |
| アイソタイプ | IgG2a | 研究分野 | Immunophenotyping | MHC |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Ms CD8A PURI,53-6.7
特異性
The rat monoclonal antibody 53-6.7 recognizes mouse CD8a antigen, a 32-34 kDa α chain of the CD8 antigen.
抗原情報
The CD8a (CD8 α) subunit of CD8 T cell coreceptor is expressed in CD8 α/β heterodimers on majority of MHC I-restricted conventional T cells and thymocytes and in CD8 α/α homodimers on subsets of memory T cells, intraepithelial lymphocytes, NK cells, macrophages and dendritic cells. Regulation of CD8 beta level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 α/β but not α/α dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affinity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Bouwer HG, Alberti-Segui C, Montfort MJ, Berkowitz ND, Higgins DE: Directed antigen delivery as a vaccine strategy for an intracellular bacterialpathogen. Proc·Natl·Acad·Sci·USA. 2006·Mar·28; 103(13):5102‑7. <·PMID:·16549792·>
• Grabbe S, Varga G, Beissert S, Steinert M, Pendl G, Seeliger S, Bloch W, Peters T, Schwarz T, Sunderkötter C, Scharffetter-Kochanek K: Beta2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J·Clin·Invest. 2002·Jan; 109(2):183‑92. <·PMID:·11805130·>
• Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S: Distinct contribution of IL‑6, TNF‑alpha, IL‑1, and IL‑10 to T cell‑mediated spontaneous autoimmune arthritis in mice. J·Clin·Invest. 2004·Aug; 114(4):582‑8. <·PMID:·15314695·>
• Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M: IL‑2 in vivo activities and antitumor efficacy enhanced by an anti‑IL‑2 mAb. J·Immunol. 2006·Jul·1; 177(1):306‑14. <·PMID:·16785526·>
• Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY: alpha‑Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J·Immunol. 2005·Sep·1; 175(5):3309‑17. <·PMID:·16116223·>
• Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol·Rev. 1979; 47:63‑90. <·PMID:·398327·>
• Ledbetter JA, Rouse RV, Micklem HS, Herzenberg LA: T cell subsets defined by expression of Lyt‑1,2,3 and Thy‑1 antigens: Two‑parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J·Exp·Med. 1980·Aug·1; 152(2):280‑95. <·PMID:·6156984·>
• Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S: Suppression of alkali burn‑induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest·Ophthalmol·Vis·Sci. 2008·May; 49(5):2172‑7. <·PMID:·18263815·>
• Takahashi K, Nakata M, Tanaka T, Adachi H, Nakauchi H, Yagita H, Okumura K: CD4 and CD8 regulate interleukin 2 responses of T cells. Proc·Natl·Acad·Sci·USA. 1992·Jun·15; 89(12):5557‑61. <·PMID:·1608966·>